Arena Pharmaceuticals Jumps After Ulcerative Colitis Trial Hits Targets
March 20, 2018 at 13:26 PM EDT
Shares of Arena Pharmaceuticals are on the rise after the company said its ulcerative colitis drug met its primary, secondary, and clinical remission endpoints in a Phase 2 trial.
